Show simple item record

dc.contributor.authorVenekamp, Roderick P
dc.contributor.authorVeldhuijzen, Irene K
dc.contributor.authorMoons, Karel G M
dc.contributor.authorVan den Bijllaardt, Wouter
dc.contributor.authorPas, Suzan D
dc.contributor.authorLodder, Esther B
dc.contributor.authorMolenkamp, Richard
dc.contributor.authorIgloi, Zsofi
dc.contributor.authorWijers, Constantijn
dc.contributor.authorDos Santos, Claudy Oliveira
dc.contributor.authorDebast, Sylvia B
dc.contributor.authorBruins, Marjan J
dc.contributor.authorPolad, Khaled
dc.contributor.authorNagel-Imming, Carla R S
dc.contributor.authorHan, Wanda G H
dc.contributor.authorvan de Wijgert, Janneke H H M
dc.contributor.authorvan den Hof, Susan
dc.contributor.authorSchuit, Ewoud
dc.date.accessioned2022-03-07T15:39:48Z
dc.date.available2022-03-07T15:39:48Z
dc.date.issued2022-02-24
dc.identifier.pmid35197052
dc.identifier.doi10.1186/s12916-022-02300-9
dc.identifier.urihttp://hdl.handle.net/10029/625595
dc.description.abstractSix thousand nine hundred fifty-five of 7005 participants (99%) with results from both an Ag-RDT and a molecular reference test were analysed. SARS-CoV-2 prevalence and overall sensitivities were 13% (188/1441) and 69% (129/188, 95% CI 62-75) for BD-Veritor, 8% (173/2056) and 69% (119/173, 61-76) for PanBio, and 12% (215/1769) and 74% (160/215, 68-80) for SD-Biosensor with routine sampling and 10% (164/1689) and 75% (123/164, 68-81) for SD-Biosensor with OP-N sampling. In those symptomatic or asymptomatic at sampling, sensitivities were 72-83% and 54-56%, respectively. Above a viral load cut-off (≥5.2 log10 SARS-CoV-2 E-gene copies/mL), sensitivities were 86% (125/146, 79-91) for BD-Veritor, 89% (108/121, 82-94) for PanBio, and 88% (160/182, 82-92) for SD-Biosensor with routine sampling and 84% (118/141, 77-89) with OP-N sampling. Specificities were >99% for all tests in most analyses. Sixty-one per cent of false-negative Ag-RDT participants returned for testing within 14 days (median: 3 days, interquartile range 3) of whom 90% tested positive.en_US
dc.language.isoenen_US
dc.rights© 2022. The Author(s).
dc.subjectCOVID-19en_US
dc.subjectDiagnostic accuracyen_US
dc.subjectRapid antigen testsen_US
dc.subjectSARS-CoV-2en_US
dc.titleDetection of SARS-CoV-2 infection in the general population by three prevailing rapid antigen tests: cross-sectional diagnostic accuracy study.en_US
dc.typeArticleen_US
dc.identifier.eissn1741-7015
dc.identifier.journalBMC medicine 2022;20(1):97en_US
dc.source.journaltitleBMC medicine
dc.source.volume20
dc.source.issue1
dc.source.beginpage97
dc.source.endpage
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record